Free tool
FAERS Monitor: Pepcid Complete
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020958 or its brand name (Pepcid Complete, Calcium Carbonate, Famotidine, Magnesium Hydroxide). Reports on generic versions are filed under their own applications.
Reports
2,416
Serious
816
34% of reports
Hospitalization
121
Death reported
74
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease483
- drug ineffective312
- acute kidney injury257
- renal failure174
- end stage renal disease133
- gastrooesophageal reflux disease133
- off label use100
- product use in unapproved indication100
- wrong technique in product usage process98
- incorrect dose administered97
- therapeutic response unexpected93
- product physical issue83
- dysgeusia78
- nausea75
- renal injury74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 9 |
| 2008 | 12 |
| 2009 | 37 |
| 2010 | 16 |
| 2011 | 18 |
| 2012 | 14 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 165 |
| 2016 | 150 |
| 2017 | 232 |
| 2018 | 254 |
| 2019 | 334 |
| 2020 | 208 |
| 2021 | 207 |
| 2022 | 143 |
| 2023 | 172 |
| 2024 | 110 |
| 2025 | 170 |
| 2026 | 134 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| end stage renal diseaseSignal | 133 | 63.9 | 54.2 | 8,125 |
| chronic kidney diseaseSignal | 483 | 55.7 | 51.4 | 25,814 |
| product physical issueSignal | 83 | 36.0 | 29.1 | 2,777 |
| renal injurySignal | 74 | 21.7 | 17.4 | 1,441 |
| therapeutic response unexpectedSignal | 93 | 18.1 | 14.8 | 1,484 |
| acute kidney injurySignal | 257 | 14.6 | 13.0 | 3,272 |
| gastrooesophageal reflux diseaseSignal | 133 | 14.4 | 12.2 | 1,649 |
| renal failureSignal | 174 | 11.4 | 9.9 | 1,652 |
| dysgeusiaSignal | 78 | 9.1 | 7.4 | 559 |
| wrong technique in product usage processSignal | 98 | 4.2 | 3.5 | 239 |
| incorrect dose administeredSignal | 97 | 3.7 | 3.0 | 190 |
| product use in unapproved indicationSignal | 100 | 3.5 | 2.9 | 179 |
| drug ineffectiveSignal | 312 | 2.1 | 1.9 | 181 |
| off label use | 100 | 1.0 | 0.8 | 0 |
| nausea | 75 | 0.8 | 0.7 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.